FDA Warnings And Restrictions On JAKs Curb Growth Potential Of Big Brands
Pfizer, AbbVie and Lilly will face new safety restrictions on Xeljanz, Rinvoq and Olumiant. Indication expansion remains uncertain, while first-line use appears out of the question.
You may also be interested in...
The company, which has struggled in the clinic following a deal where Pfizer bought its migraine portfolio, is licensing the dual inhibitor drug from a Chinese firm for up to $970m.
Safety and efficacy data show that as long as Takeda can execute effectively on a Phase III program for TAK-279, the company should be well positioned in the oral psoriasis market.
Sun outlines contours of path ahead for deuruxolitinib, which came to it via the recent $576m Concert deal and pits it against Eli Lilly's Olumiant and Pfizer's investigational candidate ritlecitinib. The Indian firm is believed to have had the JAK 1/2 inhibitor on its radar since August last year.